Corcept Therapeutics
CORT
273 hedge funds and large institutions have $2.75B invested in Corcept Therapeutics in 2023 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 26 closing their positions.
115% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 26
62% more capital inflows, than outflows
Capital inflows: $170M | Capital outflows: $105M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
22% more call options, than puts
Call options by funds: $49.6M | Put options by funds: $40.6M
11% more funds holding
Funds holding: 246 → 273 (+27)
1.81% more ownership
Funds ownership: 80.41% → 82.22% (+1.8%)
12% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 93
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.2M |
| 2 |
Man Group
London,
United Kingdom
|
+$22.7M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$12.8M |
| 4 |
QC
Quantedge Capital
Singapore
|
+$6.82M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$26.5M |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$13.4M |
| 3 |
Cerity Partners
New York
|
-$12M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.4M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$5.27M |
CORT Hedge Fund Activity: Q4 2023 in Review
273 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2023, worth a combined $2.75B — up 22% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new CORT positions and 26 closed out — a net gain of 30 holders — while 82 added to existing stakes and 93 trimmed.
The largest buyer was BlackRock, adding an estimated $33.2M. The largest seller was Novo Holdings A/S, cutting an estimated $26.5M.
- 273 institutional investors held Corcept Therapeutics (CORT) as of Q4 2023, up from 246 in Q3 2023.
- Funds reported $2.75B of Corcept Therapeutics stock for Q4 2023, up 22% quarter-over-quarter.
- 56 funds opened new Corcept Therapeutics positions in Q4 2023 and 26 closed out, a net change of +30 holders.
- The largest Corcept Therapeutics buyer in Q4 2023 was BlackRock, an estimated $33.2M added.
- The largest Corcept Therapeutics seller in Q4 2023 was Novo Holdings A/S, an estimated $26.5M sold.
Based on aggregated 13F filings for Q4 2023.